It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 26.1% in that time frame, outperforming the S&P 500. Will the recent positive ...

Acadia Pharmaceuticals said on Monday that the US Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson's ...

The 2026 GMC Acadia debuts the third model year for the third-generation crossover, introducing only minor changes over the outgoing 2025 Acadia. Among these is deletion of a specific audio system ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a ...

The 2026 GMC Acadia debuts the third model year for the third-gen crossover. Compared to the preceding 2025 GMC Acadia, the 2026 Acadia introduces relatively minor updates and changes. Among those ...

SAN DIEGO, May 27, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise.

Workers put up a chain link fence inside Acadia Montana Treatment Center, 55 Basin Creek Road in Butte. The facility was building a second fence to deter escape attempts. The troubled residential ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on ...

Overview The three-row mid-size SUV category is thick with practical options just begging to be your next family road-trip ride, and the 2026 GMC Acadia is one of the roomiest among them ...

Scott+Scott is investigating whether members of the Acadia Healthcare board of directors or senior management failed to manage Acadia Healthcare in an acceptable manner, in breach of their ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...